# Incretin hypersecretion in gestational

## diabetes mellitus

3

5

9

18

19

- 4 Short running title: Incretins in GDM
- 6 Louise Fritsche<sup>1,2</sup>, Martin Heni<sup>1,2,3,4</sup>, Sabine S. Eckstein<sup>1,2</sup>, Julia Hummel<sup>1,2</sup>, Anette
- 7 Schürmann<sup>2,5</sup>, Hans-Ulrich Häring<sup>1,2,3</sup> Hubert Preißl<sup>1,2</sup>, Andreas L. Birkenfeld<sup>1,2,3</sup>,
- 8 Andreas Peter<sup>1,2,5</sup>, Andreas Fritsche<sup>1,2,3</sup>, Robert Wagner<sup>1,2,3</sup>
- 10 1. Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center
- 11 Munich at the University of Tübingen, Tübingen, Germany
- 12 2. German Center for Diabetes Research (DZD), Neuherberg, Germany
- 13 3. Department of Internal Medicine, Division of Endocrinology, Diabetology and
- 14 Nephrology, Eberhard Karls University Tübingen, Tübingen, Germany
- Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic
- 16 Laboratory Medicine, University Hospital Tübingen, Tübingen, Germany.
- 17 5. German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany
- 20 Corresponding author
- 22 Louise Fritsche, PhD

University Hospital Tübingen, Department of Internal Medicine IV Otfried-Müller-Str. 10 72076 Tübingen Germany E-mail: louise.fritsche@med.uni-tuebingen.de Phone: +49 7071 2980687 Word count: 1482 Number of figures: 1 Number of tables: 2 Number of supplementary figures: 3 

46	Abbreviations	
47	AUC	Area under the curve
48	DPP-4	Dipeptidyl Peptidase IV
49	GDM	Gestational diabetes mellitus
50	GIP	Glucose dependent insulinotropic peptide
51	GLP-1	Glucagon like peptide-1
52	GLP-1R	Glucagon like peptide-1 receptor
53	IGI	Insulinogenic index
54	NEFA-ISI	Nonesterified fatty acids - Insulin sensitivity index
55	NGT	Normal glucose tolerance
56	OGTT	Oral glucose tolerance test

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

Abstract Background Incretins are crucial stimulators of insulin secretion after food intake. We investigated the incretin response during an oral glucose tolerance test in pregnant women with and without gestational diabetes. Methods Subjects underwent a 5-point OGTT with 75 g glucose. We assessed insulin secretion and levels of total GLP-1, GIP, glicentin and glucagon during the OGTT. Findings We examined 167 women (33 with GDM) during gestational week 26.95 ±2.15. Insulin secretion was significantly lower in women with GDM (p<0.001). Postprandial GLP-1 and GIP were ~20% higher in women with GDM (all p<0.05) independent from age, BMI and gestational age. GLP-1 increase associated with insulin secretion only in GDM, but not in NGT. Postprandial GLP-1 levels associated negatively with birth weight. Interpretation The more pronounced GLP-1 increase in women with GDM could be part of a compensatory mechanism counteracting GLP-1 resistance. Higher GLP-1 levels might be protective against fetal overgrowth. Funding This study was supported in part by a grant from the Federal Ministry of Education and Research (BMBF) (01GI0925) to the German Center for Diabetes Research (DZD).

- 81 Keywords
- 82 GDM, Incretins, GLP-1, birth weight

#### Introduction

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

Gestational diabetes mellitus (GDM) affects 13% of pregnancies with increasing incidence. In pregnancy, insulin resistance develops during the 2<sup>nd</sup> trimester and is normally compensated by an increase in insulin secretion 1. However, if this compensatory increase in insulin secretion falls short, glucose levels rise and GDM develops. When insulin resistance is resolved after delivery, glucose rapidly normalizes. Nevertheless, women who had GDM are at risk to subsequently develop type 2 diabetes <sup>2</sup>. After food intake, specialized cells in the gastrointestinal tract release incretin hormones. The best studied incretins are glucagon like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). GLP-1 is cleaved from its precursor proglucagon along with other peptides, including glicentin and oxyntomodulin. Proglucagon gene products in pancreatic α-cells give rise to glucagon. GLP-1 and GIP are strong enhancers of glucose-stimulated insulin secretion. This incretin effect is reduced in type 2 diabetes and GDM<sup>3</sup>. However, only a few studies investigated GLP-1 and GIP concentrations in GDM and reported contrasting results 4-7. One study investigated glucagon and detected higher fasting and post-glucose-challenge concentrations in GDM <sup>8</sup>. No studies on glicentin in pregnancy have been published so far. Objective The aim of our study was to investigate the response of incretins and glucagon during an oral glucose tolerance test in pregnancy in a large cohort of well phenotyped women with normal glucose tolerance and GDM using precise preanalystics and specific immunoassays.

Methods

Subjects

We analyzed data from an ongoing study aiming to characterize metabolic alterations during pregnancy (PREG), a cohort study recruiting women undergoing oral glucose tolerance tests for screening of GDM (NCT04270578). Pregnant women were examined between gestational week 24+0 and 31+6 with a 2h-OGTT with 75 g glucose. GDM was diagnosed using the IADPSG criteria <sup>9</sup> and patients were subsequently treated according to national guidelines, which was not part of the study. The detailed study protocol has been described elsewhere <sup>10</sup>. Informed written consent was obtained from every study participant. The study protocol has been approved by the local ethics boards and the study is conducted in accordance with the declaration of Helsinki. Patients were not involved in the design of the study. Meetings to connect study participants and researchers are held annually.

#### OGTT, laboratory analyses and anthropometric assessment

After an overnight fasting period of 12h, all study participants underwent 5-point OGTT with 75 g of glucose. Venous blood was collected at fasting and after 30, 60, 90 and 120 minutes. Plasma glucose and nonesterified fatty acids were measured from sodium-fluoride plasma in an ADVIA chemistry XPT autoanalyzer (Siemens Healthcare Diagnostics) at all timepoints. Serum insulin and C-peptide were analyzed using ADVIA Centaur XPT immunoassay system (Siemens AG) at all timepoints. For the measurement of total GIP, total GLP-1, glicentin and glucagon EDTA-plasma from timepoint 0, 30 and 120 minutes was stabilized with 300 ng/mL of the protease inhibitor aprotinin (Sigma, Merck, Germany) und subsequently processed at 4°C and

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

kept frozen at -80°C until batch measurement. Incretins and glucagon were measured with commercially available ELISA assays (Mercodia, Sweden) according to the manufacturer's instructions. Height and weight were measured at the day of OGTT. Pregestational weight, parity, gestational age at birth and birthweight were obtained from maternal medical logs. Birth outcome data were available from 135 participants. Insulin sensitivity was calculated using the NEFA-ISI index 11. Insulin secretion was assessed with  $\frac{AUC_{C-peptide\ 0-30}}{AUC_{Glucose\ 0-30}}$  and with  $\Delta C$ -peptide $_{0-30}$ . Statistical analysis All statistical analyses were performed with R Version 3.6.1. In linear regression models skewed variables were log-transformed to approximate normal distribution. Group differences were tested with t-tests for normal distributed variables. Kruskal-Wallis-test for non-normal distributed variables and Chi<sup>2</sup>-test for categorical variables. The provided β coefficients are standardized estimates of the linear regression model terms. A p-value <0.05 was considered statistically significant. Results We analyzed data from 167 women, in 33 GDM was diagnosed. Patients with GDM were older, more likely to be multiparous, but BMI was not different from women with normal glucose tolerance (NGT; Table 1). Glucose and hormones during OGTT Insulin secretion and sensitivity were lower in GDM (Figure 1 A, B). Areas under the curve (AUCs) of glucose and C-peptide were higher in GDM (Figure 1 C, D). While

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

fasting levels of GLP-1 and GIP were similar, the levels at 30min were higher in GDM (Table 2). The AUCs of GLP-1 and GIP were also higher in GDM (all p<0.05, Figure 1 E, F, Table 2). Fasting glicentin, glucagon, and their post-load kinetics were not different between groups (p ≥0.1, Figure 1 G, H, Table 2). GLP-1 associates with insulin secretion only in women with GDM We hypothesized that higher incretin levels in GDM represent a compensatory effect to boost insulin secretion. Therefore, we analyzed the associations of GLP-1 and glucose with insulin secretion (Figure S1). In NGT, increase in glucose between 0-30min associated with insulin secretion (Figure S1 A, p<0.0001). No such association was present for GLP-1 (panel B, p=0.43). In contrast, women with GDM showed no association of glucose (Figure S1 C, p=0.6) but a positive association of GLP-1 with insulin secretion (panel D, p=0.0004). This remained significant after adjustment for glucose change and basal insulin. Glicentin was similarly associated with insulin secretion in GDM and NGT (Figure S2). For GIP there was no association with insulin secretion (Figure S3). Higher GLP-1 associates with lower birth weight Birth weight negatively associated with AUC GLP-1 (p=0.0182, β=-76.94), 30min GLP-1 (p=0.0248,  $\beta$ =-72.6) and trend for negative association with 30min GIP (p=0.0814,  $\beta$ =-57.45, all models adjusted for gestational age at birth, fetal sex and pregestational BMI). Since GLP-1 and GIP concentrations were higher in GDM, the models were additionally adjusted for GDM. Associations of birth weight with AUC GLP-1 and 30min GLP-1 remained significant (p=0.0296,  $\beta$ =-72.43 and p=0.0381,  $\beta$ =-68.49, respectively).

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

Discussion Main findings In this study, we find significantly higher postprandial GLP-1 and GIP levels in pregnant women with gestational diabetes compared to women with normal glucose tolerance, independent from age, body mass index and gestational age. The postprandial GLP-1 increase associated with insulin secretion in women with GDM but not in women with NGT, where insulin secretion was glucose driven. Offspring of women with higher GLP-1 levels also had lower birth weights. Interpretation GLP-1 and GIP have previously been investigated in women with and without GDM in smaller studies with different results <sup>4,6,7,12</sup>. One study used a different stimulus (mixed meal test) <sup>6</sup> and large BMI differences <sup>6,12</sup> between NGT and GDM subjects might further confound analyses, because BMI negatively associates with GLP-1 and GIP <sup>13</sup>. Similar BMI between groups allowed analyzing impact of GDM on incretin responses, without adiposity as confounder. Intestinal L-cells also secrete glicentin, a potential biomarker of L-cell secretion <sup>14</sup>. Lack of difference in glicentin between NGT and GDM argues against an unselective L-cell hypersecretion in GDM. In contrast to findings on glucagon outside of pregnancy <sup>15</sup>, we and others <sup>6</sup> did not detect links to diabetes. This argues against a major contribution of glucagon in the pathogenesis of GDM, while it might have some value in the prognosis of subsequent insulin requirement for the treatment of GDM <sup>16</sup>. Of note, women with GDM had lower insulin secretion despite higher GLP-1 concentrations. Our correlational analyses indicate an important contribution of GLP-1 to insulin secretion, especially in GDM. However, this GLP-1 stimulus is still not

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

sufficient to control hyperglycemia. The failure of adequate insulin secretion despite elevated GLP-1 indicates incretin resistance in GDM. The more pronounced GLP-1 response in GDM could be counteracting incretin resistance. potential contributor to incretin resistance is genetic background. One Polymorphisms in TCF7L2 associate with elevated GDM risk <sup>17</sup> and reduced GLP-1stimulated insulin secretion <sup>18</sup>. Another possible contributor might be dipeptidyl peptidase IV (DPP-4) activity, the enzyme degrading GLP-1 and GIP. Liu et al. 19 reported no differences of DPP-4 in maternal serum and the unaltered fasting GLP-1 levels in GDM in our study argue against largely different DPP-4 activity. Furthermore, insulin resistance and hyperglycemia which are present in GDM are associated with incretin resistance <sup>18</sup>. In our study neonates of women with higher GLP-1 levels during pregnancy had lower birth weight, independent of glycemia. This points towards a protection of GLP-1 against excessive fetal growth. Our findings are in line with a report of negative association between fasting maternal GLP-1 and fetal abdominal circumference and birth weight <sup>20</sup>. Higher GLP-1, also via decelerated gastric emptying, might reduce postprandial glucose which is associated with fetal overgrowth. If this hypothesis holds true, GLP-1 receptor agonists or DPP-4 inhibitors might have benefits in GDM. To our knowledge, currently no studies test GLP-1R agonists in GDM. One trial reported higher insulin secretion after 16 weeks treatment with the DPP-4 inhibitor sitagliptin in GDM <sup>21</sup>. However, neither incretins nor birth outcomes were reported. Strengths and limitations The strength of our study is the large number of subjects of our extensively phenotyped cohort of pregnant women. The sample preparation and measurement of incretins was done according to standard operating procedures and with state-of-the-

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

art measuring method. One weakness is the relatively low number of patients with GDM. Conclusion In summary, elevated GLP-1 could be part of a compensatory attempt to counteract GLP-1 resistance in GDM. Higher GLP-1 levels might protect against fetal overgrowth. Our data suggest that not only glucose-stimulated but also incretinstimulated insulin secretion contributes to GDM. Further studies are needed to translate these findings into improved therapeutic strategies to prevent or treat GDM and circumvent unfavorable impact on the developing child. Acknowledgement We thank all of the volunteers for their participation in the study. We especially thank Ines Wagener, Eva-Maria Stehle, Alexandra Eberle, Dorothee Neuscheler, Henrike Peuker, Elisabeth Metzinger and Heike Runge for their excellent technical assistance. Disclosure of interests RW reports lecture fees from NovoNordisk and travel grants from Eli Lilly. He served on the advisory board of Akcea Therapeutics. In addition to his current work, ALB reports lecture fees from Astra Zeneca, Boehringer Ingelheim, and NovoNordisk. He served on advisory boards of Astra Zeneca, Boehringer Ingelheim and NovoNordisk. Besides his current work, AF reports lecture fees and advisory board membership from Sanofi, Novo Nordisk, Eli Lilly, and AstraZeneca. In addition to is current work,

MH reports research grants from Boehringer Ingelheim and Sanofi (both to the University Hospital of Tuebingen) and lecture fees from Sanofi, Novo Nordisk, Eli Lilly and Merck Sharp Dohme. None of the other authors report a conflict of interest directly related to the content of this work.

### Contribution of authorship

LF researched and analyzed data and drafted the manuscript. JH, SN, and RW researched data. HUH, ALB, HP, AS, and AF contributed to the discussion and interpretation of the results. AP supervised the laboratory measurements and interpreted results. RW and MH supervised the project. All authors contributed to discussion and approved the final manuscript prior to submission. RW is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

## **Details of Ethics Approval**

- The study protocol has been approved by the ethics board of the University of
- 272 Tuebingen (No. 218/2012BO2, 06/15/2012).

### Funding

- 275 This study was supported in part by a grant from the Federal Ministry of Education
- and Research (BMBF) (01GI0925) to the German Center for Diabetes Research
- 277 (DZD).

Registration 279 280 The PREG Study is registered with clinicaltrials.gov NCT 04270578. 281 Data availability 282 283 All requests for data and materials will be promptly reviewed by the Data Access 284 Steering Committee to verify whether the request is subject to any intellectual 285 property or confidentiality obligations. Individual-level data may be subject to 286 confidentiality. Any data and materials that can be shared will be released via a 287 Material Transfer Agreement. 288 289 References 290 291 292 Powe CE, Huston Presley LP, Locascio JJ, Catalano PM. Augmented insulin 293 secretory response in early pregnancy. Diabetologia. 2019 Aug 1;62(8):1445-294 52. 295 Kim C, Newton KM, Knopp RH. Gestational Diabetes and the Incidence of Type 296 2 Diabetes. Diabetes Care. 2002 Oct 1;25(10):1862-8. 297 3. Kosinski M, Knop FK, Vedtofte L, Grycewiczy J, Swierzewska P, Cypryk K, et al. 298 Postpartum reversibility of impaired incretin effect in gestational diabetes 299 mellitus. Regulatory Peptides. 2013 Sep 10;186:104-7.

- 300 4. Cypryk K, Vilsbøll T, Nadel I, Smyczyńska J, Holst JJ, Lewiński A. Normal
- 301 secretion of the incretin hormones glucose-dependent insulinotropic polypeptide
- and glucagon-like peptide-1 during gestational diabetes mellitus. Gynecological
- 303 Endocrinology. 2007 Jan 1;23(1):58–62.
- 304 5. Mosavat M, Omar SZ, Jamalpour S, Tan PC. Serum Glucose-Dependent
- 305 Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) in
- association with the Risk of Gestational Diabetes: A Prospective Case-Control
- 307 Study. Adamska-Patruno E, editor. Journal of Diabetes Research. 2020 Jan
- 308 29;2020:9072492.
- 309 6. Bonde L, Vilsbøll T, Nielsen T, Bagger JI, Svare JA, Holst JJ, et al. Reduced
- 310 postprandial GLP-1 responses in women with gestational diabetes mellitus.
- 311 Diabetes, Obesity and Metabolism. 2013;15(8):713–20.
- 312 7. Lencioni C, Resi V, Romero F, Lupi R, Volpe L, Bertolotto A, et al. Glucagon-like
- peptide-1 secretion in women with gestational diabetes mellitus during and after
- 314 pregnancy. J Endocrinol Invest. 2011 Oct;34(9):e287-290.
- 315 8. Beis C, Grigorakis SI, Philippou G, Alevizaki M, Anastasiou E. Lack of
- 316 suppression of plasma glucagon levels in late pregnancy persists postpartum
- only in women with previous gestational diabetes mellitus. Acta Diabetol. 2005
- 318 Mar;42(1):31–5.
- 319 9. International Association of Diabetes and Pregnancy Study Groups Consensus
- Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al.
- 321 International association of diabetes and pregnancy study groups

- recommendations on the diagnosis and classification of hyperglycemia in
- 323 pregnancy. Diabetes Care. 2010 Mar;33(3):676–82.
- 10. Fritsche L, Hummel J, Wagner R, Loeffler D, Hartkopf J, Machann J, et al. The
- 325 German Gestational Diabetes Study (PREG): Rationale, Methodology and
- 326 Design [Internet]. 2021 [cited 2021 Oct 12]. p. 2021.10.10.21264499. Available
- 327 from: https://www.medrxiv.org/content/10.1101/2021.10.10.21264499v1
- 328 11. Wagner R, Fritsche L, Heni M, Fehlert E, Stefan N, Staiger H, et al. A novel
- insulin sensitivity index particularly suitable to measure insulin sensitivity during
- 330 gestation. Acta Diabetol. 2016 Dec;53(6):1037–44.
- 331 12. Sukumar N, Bagias C, Goljan I, Weldeselassie Y, Gharanei S, Tan BK, et al.
- 332 Reduced GLP-1 Secretion at 30 Minutes After a 75-g Oral Glucose Load Is
- Observed in Gestational Diabetes Mellitus: A Prospective Cohort Study.
- 334 Diabetes. 2018 Dec 1;67(12):2650–6.
- 335 13. Færch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A, et al.
- 336 GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected
- Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO
- 338 Study. Diabetes. 2015 Jul;64(7):2513–25.
- 14. Perakakis N, Mantzoros CS. The Role of Glicentin and Oxyntomodulin in Human
- 340 Metabolism: New Evidence and New Directions. J Clin Endocrinol Metab. 2020
- 341 Aug 1:105(8):e3003–5.
- 342 15. Wagner R, Hakaste LH, Ahlqvist E, Heni M, Machann J, Schick F, et al.
- Nonsuppressed Glucagon After Glucose Challenge as a Potential Predictor for
- 344 Glucose Tolerance. Diabetes. 2017 May 1;66(5):1373–9.

- 16. Horie I, Haraguchi A, Ito A, Nozaki A, Natsuda S, Akazawa S, et al. Impaired
- early-phase suppression of glucagon secretion after glucose load is associated
- with insulin requirement during pregnancy in gestational diabetes. J Diabetes
- 348 Investig. 2020 Jan;11(1):232–40.
- 349 17. Fritsche L, Sarief M, Wagner R, Stefan N, Lehmann R, Häring H-U, et al.
- Genetic variation in TCF7L2 rs7903146 and history of GDM negatively and
- independently impact on diabetes-associated metabolic traits. Diabetes Res Clin
- 352 Pract. 2018 Dec;146:251–7.
- 353 18. Herzberg-Schäfer S, Heni M, Stefan N, Häring H-U, Fritsche A. Impairment of
- 354 GLP1-induced insulin secretion: role of genetic background, insulin resistance
- and hyperglycaemia. Diabetes, Obesity and Metabolism. 2012;14(s3):85–90.
- 356 19. Liu B, Deng S, Xu Y, Yang J, Geng H, Wang Z. Association between maternal
- 357 and umbilical cord serum dipeptidyl peptidase IV in pregnant women with and
- 358 without gestational diabetes mellitus. Journal of Obstetrics and Gynaecology
- 359 Research. 2016;42(5):505–10.
- 360 20. Valsamakis G, Margeli A, Vitoratos N, Boutsiadis A, Sakkas EG, Papadimitriou
- G, et al. The role of maternal gut hormones in normal pregnancy: fasting plasma
- active glucagon-like peptide 1 level is a negative predictor of fetal abdomen
- 363 circumference and maternal weight change. European Journal of Endocrinology.
- 364 2010 May 1;162(5):897–903.
- 365 21. Sun X, Zhang Z, Ning H, Sun H, Ji X. Sitagliptin down-regulates retinol-binding
- 366 protein 4 and reduces insulin resistance in gestational diabetes mellitus: a
- randomized and double-blind trial. Metab Brain Dis. 2017 Jun 1;32(3):773–8.

Figure 1 Insulin secretion (A) and insulin sensitivity (B) in women with and without GDM and time course of glucose (C), C-peptide (D), GLP-1 (E), GIP (F), glicentin (G) and glucagon (H) during OGTT. Data are presented as mean ± standard error. Blue represent NGT, red GDM. Group differences between GDM and NGT for AUCs of glucose, insulin and C-peptide were tested with Kruskal-Wallis-test. Differences between groups for insulin sensitivity, incretins and glucagon were tested with multivariate linear regression adjusted for age, BMI and gestational week and for insulin secretion additionally adjusted for insulin sensitivity.

#### **Tables**

#### Table 1 Subject characteristics of the pregnant cohort and birth outcome parameters

Characteristics	NGT (n = 134)	GDM (n = 33)	р	p adjusted
Age	32.71 (4.31)	35.03 (3.84)	0.005*	-
BMI (kg/m²)	26.90 [23.97, 29.94]	26.90 [24.72, 30.99]	0.497	-
Pregestational BMI (kg/m²)	25.37 (5.25)	25.50 (4.96)	0.906	-
Gestational weight gain (kg)	14.06 (5.53)	11.46 (7.10)	0.085	-
Parity (%) Nulliparous Multiparous	69 (51.5) 65 (48.5)	9 (27.37) 24 (72.7)	0.021*	-
Gestational age at OGTT (weeks)	26.87 (2.16)	27.27 (2.11)	0.332	-
Fasting glucose (mmol/L)	4.28 [4.07, 4.54]	4.56 [4.33, 4.94]	<0.001*	-
1 h glucose (mmol/L)	7.70 [6.40, 8.56]	10.61 [9.56, 11.33]	<0.001*	-
2 h glucose (mmol/L)	6.11 [5.34, 6.83]	8.83 [7.72, 9.44]	<0.001*	-
Fasting insulin (pmol/L)	59 [42, 79]	69[41, 84]	0.460	-
Fasting C-peptide (pmol/L)	381.50 [296.50, 496.50]	466.00 [282.00, 652.00]	0.150	-
Insulin sensitivity (NEFA-ISI)	3.34 [2.56, 4.39]	2.72 [2.01, 4.26]	0.031*	0.003*†
Insulin secretion (AUC <sub>C-pep 0-30</sub> / AUCGlucose0- 30)	179.22 (60.12)	155.17 (54.53)	0.037*	<0.001*‡
Birth weight (g) #	3478.18 (479.84)	3321.52 (384.38)	0.084	0.24 §
Birth length (cm) #	51.48 (2.37)	50.48 (2.68)	0.042	0.27 §
Gestational age at birth (weeks) <sup>4</sup>	39.51 (1.59)	39.16 (1.17)	0.240	-

Data are presented as means (SD), median [IQR] and numbers (%). Group differences were tested with T-test for normal distributed variables, Kruskal-Wallistest for nonnormal distributed variables and Chi2-test for categorical variables. \*indicates statistical significance. † Adjusted for age, BMI and gestational age, ‡ adjusted for age, BMI, gestational age and insulin sensitivity, § adjusted for gestational age and fetal sex, # n=135. NGT = normal glucose tolerance.

## Table 2 Incretin concentrations during OGTT and AUCs in the pregnant cohort

Incretin	NGT (n = 134)	GDM (n = 33)	р	p adjusted †
GLP-1 min 0 (pmol/L)	4.48 [3.42, 5.53]	4.83 [3.56, 6.18]	0.393	0.6
GLP-1 min 30 (pmol/L)	9.89 [7.10, 12.83]	11.31 [8.65, 14.98]	0.034*	0.03*
GLP-1 min 120 (pmol/L)	5.71 [4.55, 8.27]	6.48 [5.05, 9.30]	0.175	0.3
AUC GLP-1 (min-pmol/L)	911.19 [726.59, 1207.49]	1136.24 [913.21, 1342.74]	0.03*	0.03*
GIP min 0 (pmol/L)	0.81 [0.81, 1.50]	0.81 [0.81, 1.76]	0.312	0.5
GIP min 30 (pmol/L)	20.21 [14.12, 29.69]	24.12 [18.76, 35.77]	0.049*	0.02*
GIP min 120 (pmol/L)	17.48 [11.92, 23.58]	19.20 [14.96, 27.13]	0.191	0.1
AUC GIP (min-pmol/L)	2022.49 [1421.28, 2887.34]	2532.15 [1899.17, 3219.01]	0.045*	0.04*
Glicentin min 0 (pmol/L)	12.37 [8.53, 16.92]	12.59 [9.56, 16.56]	0.989	0.9
Glicentin min 30 (pmol/L)	25.10 [19.26, 34.73]	28.33 [25.16, 35.13]	0.122	0.1
Glicentin min 120 (pmol/L)	20.17 [14.97, 30.45]	21.66 [14.44, 29.84]	0.602	0.3
AUC Glicentin (min-pmol/L)	2715.75 [2092.97, 3529.69]	2912.80 [2426.76, 3574.03]	0.198	0.1
Glucagon min 0 (pmol/L)	1.45 [0.81, 3.42]	1.43 [0.95, 2.96]	0.873	0.6

Glucagon min 30 (pmol/L)	1.35 [0.55, 2.20]	1.15 [0.78, 2.54]	0.550	0.4
Glucagon min 120 (pmol/L)	0.91 [0.44, 1.53]	0.74 [0.46, 1.50]	1.000	0.9
AUC Glucagon (min-pmol/L)	139.11 [74.68, 236.32]	124.74 [89.05, 262.70]	0.659	0.9

Data are presented as median [IQR]. Simple group differences were tested with Kruskal-Wallis-test. † adjusted for age, BMI and gestational week. \*indicates statistical significance.

Fig.1

